AnaptysBio director exercises 6,030 RSUs

ANAPTYSBIO director John P. Schmid exercised restricted stock units into common shares.

Rhea-AI Filing Summary

ANAPTYSBIO director John P. Schmid exercised restricted stock units into common shares. On June 15, 2026 he converted 6,030 RSUs into 6,030 shares of common stock for no cash consideration. Following the transaction, he holds 37,652 common shares directly, with no remaining RSU position reported.

Insights

Insider transactions analyst

Routine RSU vesting and share acquisition with no share sale.

Director John P. Schmid exercised 6,030 restricted stock units, receiving the same number of ANAPTYSBIO common shares at no cash cost. This reflects compensation vesting rather than an open-market purchase.

The filing shows no sales, gifts, or tax-withholding dispositions associated with this exercise. After settlement, Schmid directly owns 37,652 common shares. With no remaining derivative holdings reported, this appears to be a standard RSU vesting event with neutral informational value for investors.

Insider Trade Summary

6,030 shares exercised/converted

Exercise 2 txns

Insider Schmid John P.

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Unit	6,030	$0.00	$0.00
Exercise	Common Stock	6,030	$0.00	$0.00

Holdings After Transaction: Restricted Stock Unit — 0 contracts (Direct); Common Stock — 37,652 shares (Direct)

Footnotes (2)

1. F1. Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
2. F2. The RSUs vests as to 100% of the total RSUs on June 15, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Key Figures

RSUs exercised: 6,030 units Common shares acquired: 6,030 shares Post-transaction holdings: 37,652 shares +2 more

5 metrics

RSUs exercised 6,030 units Restricted Stock Units settled into common stock on June 15, 2026

Common shares acquired 6,030 shares Shares received upon RSU settlement on June 15, 2026

Post-transaction holdings 37,652 shares Common stock directly owned after the RSU exercise

RSU conversion price $0.00 per share Each RSU converts into one share for no consideration

Vesting date June 15, 2026 RSUs vest 100% on this date, subject to continued service

Key Terms

Restricted Stock Unit, derivative security, contingent right, vests as to 100%

4 terms

Restricted Stock Unit financial

"Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

derivative security financial

"transaction_code_description: Exercise or conversion of derivative security"

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

contingent right financial

"represents a contingent right to receive 1 share of the Issuer's Common Stock"

vests as to 100% financial

"The RSUs vests as to 100% of the total RSUs on June 15, 2026"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ANAB director John P. Schmid report?

Director John P. Schmid reported exercising 6,030 restricted stock units into 6,030 shares of ANAPTYSBIO common stock. The transaction reflects settlement of equity compensation rather than an open-market trade, and was reported as a derivative exercise on June 15, 2026.

How many ANAPTYSBIO (ANAB) shares does John P. Schmid own after this Form 4?

After the reported RSU exercise, John P. Schmid directly owns 37,652 shares of ANAPTYSBIO common stock. This total reflects his holdings following conversion of 6,030 restricted stock units, with no remaining RSU balance shown in the filing’s derivative section.

Did ANAB director John P. Schmid buy or sell shares in the open market?

The Form 4 does not show any open-market buys or sells by John P. Schmid. Instead, it records a derivative exercise where 6,030 restricted stock units were settled into 6,030 common shares at no cash price, a routine equity compensation event.

What are the terms of the ANAB restricted stock units in this filing?

Each restricted stock unit represents a contingent right to receive one share of ANAPTYSBIO common stock for no consideration. The RSUs vest 100% on June 15, 2026, conditioned on the reporting person continuing to provide service to the company through the vesting date.

How is the RSU vesting schedule described for ANAPTYSBIO (ANAB)?

The filing states the restricted stock units vest as to 100% of the total RSUs on June 15, 2026. Vesting is subject to the reporting person’s continued service to ANAPTYSBIO through that vesting date, after which each RSU converts into one share of common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/17/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Schmid John P.

(Last) (First) (Middle)

C/O ANAPTYSBIO, INC.

10770 WATERIDGE CIRCLE, SUITE 210

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ANAPTYSBIO, INC [ ANAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/15/2026		M		6,030	A	$0(1)	37,652	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	06/15/2026		M			6,030	(2)	(2)	Common Stock	6,030	$0	0	D

Explanation of Responses:

1. Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.

2. The RSUs vests as to 100% of the total RSUs on June 15, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

	/s/ Christopher Murphy, Attorney-in-Fact	06/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)